<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+ 1.6a) -->
     <!-- Project:        I:\CONVER\ny13020.eep                                            -->
     <!-- Control Number: ny13020                                                          -->
     <!-- Rev Number:     8-K                                                              -->
     <!-- Client Name:    Advanced Medical Optics                                          -->
     <!-- Project Name:   ny13020                                                          -->
     <!-- Firm Name:      Advanced Medical Optics                                          -->
     <TITLE>8-K</TITLE>
</HEAD>
<BODY>
<BR><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>UNITED
STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, D.C. 20549</B>  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>FORM
8-K </B> </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>CURRENT
REPORT<BR>Pursuant to Section 13 or 15(d) of the<BR> Securities Exchange Act of 1934</B>  </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date
of Report (Date of earliest event reported):&nbsp;&nbsp;June 17, 2004<!-- DATE --> </FONT></TD></TR>
</TABLE>
<BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
<B>ADVANCED MEDICAL OPTICS, INC.<!-- Name of Registrant --></B></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="8k Cover table 3" FSL="Project" -->
<TABLE WIDTH="600" CELLPADDING="0" CELLSPACING="0" BORDER="0">
<tr Valign=BOTTOM>
<TD WIDTH="33%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>Delaware</B><!-- State--></font></td>
<TD WIDTH="34%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>01-31257</B><!-- File No.--></font></td>
<TD WIDTH="33%" ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2><B>33-0986820</B><!-- Irs No.--></font></td>
</tr>
<tr Valign=TOP>
<TD ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(State or other jurisdiction <br>of incorporation)</font></td>
<td ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(Commission<br>File Number) </font></td>
<TD ALIGN="CENTER"><Font Face="Times New Roman, Times, Serif" Size=2>(IRS Employer<br> Identification No.) </font></td>
</tr>
</table>
<BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="70%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>1700 E. St. Andrew Place<BR>
Santa Ana, CA</B><!-- ADDRESS --></FONT></TD>
     <TD WIDTH="10%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="20%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>92705</B><!-- ZIP CODE --></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Address of principal executive offices)</FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Zip Code)</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Registrant's
telephone number, including area code:&nbsp;&nbsp;<B>(714) 247-8200</B>&nbsp;
<!-- TELEPHONE NO. --></FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Former
name or former address, if changed since last report)  </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Events and Regulation FD Disclosure.</FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June 17, 2004, Advanced Medical Optics, Inc. issued a press release, attached hereto as
Exhibit&nbsp;99.1 and by this reference incorporated herein, announcing that it had
priced its previously announced private offering of convertible senior subordinated notes
due 2024.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.</FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 0" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit 99.1 </FONT></TD>
<TD WIDTH=92%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press Release, dated June 17, 2004, issued by Advanced Medical Optics, Inc. </FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.  </FONT></TD></TR></TABLE><BR>





<!-- MARKER FORMAT-SHEET="Company Right" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="8%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- TYPE "DATE:" HERE--> </FONT></TD>
    <TD WIDTH="44%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="48%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">ADVANCED MEDICAL OPTICS, INC.<BR>
(Registrant)<!-- COMPANY --> </FONT></TD>
  </TR>
</TABLE>
<BR>




<!-- MARKER FORMAT-SHEET="Date By Signature" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="8%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Date: </FONT></TD>
    <TD WIDTH="39%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">June 17, 2004 <!-- DATE--> </FONT></TD>
    <TD WIDTH="5%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="5%" VALIGN="TOP"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By: </FONT></TD>
    <TD WIDTH="43%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;<U>/s/ Aimee S. Weisner&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Aimee S. Weisner<BR>Corporate Vice President,<BR>
General Counsel and Secretary<!-- NAME --> </FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
  </TR>
</TABLE>



<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>




<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT
INDEX </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit<BR>
No.</B> </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>       99.1  </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Press
Release, dated June 17, 2004, issued by Advanced Medical Optics, Inc. </FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit
99.1</B> </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2><IMG SRC="adv.jpg"> </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>FOR
IMMEDIATE RELEASE</FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 0" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Investor Contact:</FONT></TD>
<TD WIDTH=80%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Sheree Aronson<BR>
(714) 247-8290<BR>
sheree.aronson@amo-inc.com</FONT></TD>
</TR>
</TABLE>
<BR>




<!-- MARKER FORMAT-SHEET="Para Hang 0" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Media Contact:</FONT></TD>
<TD WIDTH=80%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Steve Chesterman <BR>
(714) 247-8711 <BR>
steve.chesterman@amo-inc.com</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ADVANCED
MEDICAL OPTICS, INC. <BR>
PRICES $300 MILLION <BR>
CONVERTIBLE
SENIOR SUBORDINATED NOTES OFFERING </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(SANTA
ANA, CA), June 17, 2004 &#151; Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], today
announced that it had priced a private offering of $300 million aggregate principal amount of
its 2.5% convertible senior subordinated notes due 2024 ($350 million
aggregate principal amount of notes if the initial purchasers exercise their option in
full). The notes will be unsecured senior subordinated obligations of AMO. The notes were
offered only to qualified institutional buyers pursuant to Rule 144A under the Securities
Act of 1933. The sale of the notes is expected to close on June 22, 2004, subject to
customary closing conditions. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
notes will pay interest semi-annually in arrears at an annual rate of 2.5%
and will be convertible under certain circumstances into shares of AMO&#146;s common stock
at an initial conversion price of approximately $50.24 per share (an initial
conversion rate of 19.9045 shares per $1,000 principal amount of notes). The initial
conversion price represents an approximately 34% premium to the $37.49
per share closing price of AMO&#146;s common stock on The New York Stock Exchange on June
16, 2004. Upon conversion, AMO will have the right to deliver, in lieu of shares of its
common stock, cash or a combination of cash and shares of its common stock. AMO also will
have the right to irrevocably elect to satisfy its conversion obligation with respect to
the principal amount of the notes to be converted in cash, with any remaining amount to be
satisfied in shares of its common stock. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AMO
intends to use up to approximately $84 million of the net proceeds of the offering to
repurchase up to all of the $70 million aggregate principal amount of its outstanding
9&frac14; percent senior subordinated notes due 2010 and to make the related consent
payments pursuant to a cash tender offer and consent solicitation commenced on June 9,
2004 and the remainder to fund a portion of the purchase price for AMO&#146;s pending
acquisition of the ophthalmic surgical business of Pfizer Inc. and for general corporate
purposes. The actual amount used in the tender offer will depend on the number of tenders
received by AMO and may vary from the above amount. The acquisition of Pfizer&#146;s
ophthalmic surgical business is subject to customary closing conditions. The offering is
not conditioned on completion of the tender offer and consent solicitation or the
acquisition. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
notes and the shares of common stock issuable on conversion of the notes have not been
registered under the Securities Act of 1933 or any state securities laws and unless so
registered may not be offered or sold in the United States except pursuant to an exemption
from, or in a transaction not subject to, the registration requirements of the Securities
Act of 1933 and applicable state securities laws. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Forward-Looking
Statements</FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This
press release contains forward-looking statements about AMO, including those relating to
the offering, the tender offer and consent solicitation and the pending acquisition of the
ophthalmic surgical business of Pfizer Inc. and whether or not AMO will consummate the
offering, the tender offer and consent solicitation or the acquisition. All
forward-looking statements in this press release are based on estimates and assumptions
and represent AMO&#146;s judgment only as of the date of this press release. Actual
results may differ from current expectations based on a number of factors including but
not limited to changing market conditions, AMO&#146;s ability to complete the offering,
the tender offer and consent solicitation or the acquisition. In addition, matters
generally affecting the domestic and global economy, such as changes in interest and
currency exchange rates, can affect AMO&#146;s results. Therefore, the reader is cautioned
not to rely on these forward-looking statements. AMO disclaims any intent or obligation to
update these forward-looking statements. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO&#146;s public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading &#147;Certain Factors and
Trends Affecting AMO and its Businesses&#148; in AMO&#146;s 2003 Form 10-K filed by AMO
with the Securities and Exchange Commission (the &#147;Commission&#148;) on March 12, 2004
and AMO&#146;s Form 10-Q for the quarterly period ended March 26, 2004, filed by AMO with
the Commission on May 3, 2004, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling (714) 247-8348. </FONT></TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>#
# # </FONT></TD></TR>
</TABLE>
<BR>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "los342602.htm", "description": "FORM 8-K", "secsgml_size_bytes": 19104}]
{"company-data": {"conformed-name": "ADVANCED MEDICAL OPTICS INC", "cik": "0001168335", "assigned-sic": "3841", "irs-number": "330986820", "state-of-incorporation": "DE"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-31257", "film-number": "04868188"}, "business-address": {"street1": "1700 E. ST. ANDREW PL.", "city": "SANTA ANA", "state": "CA", "zip": "92705", "phone": "714-247-8200"}}
8-K
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):  June 17, 2004
ADVANCED MEDICAL OPTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
01-31257
33-0986820
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1700 E. St. Andrew Place
Santa Ana, CA
92705
(Address of principal executive offices)
(Zip Code)
Registrant's
telephone number, including area code:
(714) 247-8200
(Former
name or former address, if changed since last report)
Item
5.      Other Events and Regulation FD Disclosure.
On
June 17, 2004, Advanced Medical Optics, Inc. issued a press release, attached hereto as
Exhibit 99.1 and by this reference incorporated herein, announcing that it had
priced its previously announced private offering of convertible senior subordinated notes
due 2024.
Item
7.      Financial Statements and Exhibits.
Exhibit 99.1
Press Release, dated June 17, 2004, issued by Advanced Medical Optics, Inc.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
ADVANCED MEDICAL OPTICS, INC.
(Registrant)
Date:
June 17, 2004
By:
/s/ Aimee S. Weisner
Aimee S. Weisner
Corporate Vice President,
General Counsel and Secretary
EXHIBIT
INDEX
Exhibit
No.
99.1
Press
Release, dated June 17, 2004, issued by Advanced Medical Optics, Inc.
Exhibit
99.1
FOR
IMMEDIATE RELEASE
Investor Contact:
Sheree Aronson
(714) 247-8290
sheree.aronson@amo-inc.com
Media Contact:
Steve Chesterman
(714) 247-8711
steve.chesterman@amo-inc.com
ADVANCED
MEDICAL OPTICS, INC.
PRICES $300 MILLION
CONVERTIBLE
SENIOR SUBORDINATED NOTES OFFERING
(SANTA
ANA, CA), June 17, 2004 — Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], today
announced that it had priced a private offering of $300 million aggregate principal amount of
its 2.5% convertible senior subordinated notes due 2024 ($350 million
aggregate principal amount of notes if the initial purchasers exercise their option in
full). The notes will be unsecured senior subordinated obligations of AMO. The notes were
offered only to qualified institutional buyers pursuant to Rule 144A under the Securities
Act of 1933. The sale of the notes is expected to close on June 22, 2004, subject to
customary closing conditions.
The
notes will pay interest semi-annually in arrears at an annual rate of 2.5%
and will be convertible under certain circumstances into shares of AMO's common stock
at an initial conversion price of approximately $50.24 per share (an initial
conversion rate of 19.9045 shares per $1,000 principal amount of notes). The initial
conversion price represents an approximately 34% premium to the $37.49
per share closing price of AMO's common stock on The New York Stock Exchange on June
16, 2004. Upon conversion, AMO will have the right to deliver, in lieu of shares of its
common stock, cash or a combination of cash and shares of its common stock. AMO also will
have the right to irrevocably elect to satisfy its conversion obligation with respect to
the principal amount of the notes to be converted in cash, with any remaining amount to be
satisfied in shares of its common stock.
AMO
intends to use up to approximately $84 million of the net proceeds of the offering to
repurchase up to all of the $70 million aggregate principal amount of its outstanding
9¼ percent senior subordinated notes due 2010 and to make the related consent
payments pursuant to a cash tender offer and consent solicitation commenced on June 9,
2004 and the remainder to fund a portion of the purchase price for AMO's pending
acquisition of the ophthalmic surgical business of Pfizer Inc. and for general corporate
purposes. The actual amount used in the tender offer will depend on the number of tenders
received by AMO and may vary from the above amount. The acquisition of Pfizer's
ophthalmic surgical business is subject to customary closing conditions. The offering is
not conditioned on completion of the tender offer and consent solicitation or the
acquisition.
The
notes and the shares of common stock issuable on conversion of the notes have not been
registered under the Securities Act of 1933 or any state securities laws and unless so
registered may not be offered or sold in the United States except pursuant to an exemption
from, or in a transaction not subject to, the registration requirements of the Securities
Act of 1933 and applicable state securities laws.
Forward-Looking
Statements
This
press release contains forward-looking statements about AMO, including those relating to
the offering, the tender offer and consent solicitation and the pending acquisition of the
ophthalmic surgical business of Pfizer Inc. and whether or not AMO will consummate the
offering, the tender offer and consent solicitation or the acquisition. All
forward-looking statements in this press release are based on estimates and assumptions
and represent AMO's judgment only as of the date of this press release. Actual
results may differ from current expectations based on a number of factors including but
not limited to changing market conditions, AMO's ability to complete the offering,
the tender offer and consent solicitation or the acquisition. In addition, matters
generally affecting the domestic and global economy, such as changes in interest and
currency exchange rates, can affect AMO's results. Therefore, the reader is cautioned
not to rely on these forward-looking statements. AMO disclaims any intent or obligation to
update these forward-looking statements.
Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO's public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading "Certain Factors and
Trends Affecting AMO and its Businesses" in AMO's 2003 Form 10-K filed by AMO
with the Securities and Exchange Commission (the "Commission") on March 12, 2004
and AMO's Form 10-Q for the quarterly period ended March 26, 2004, filed by AMO with
the Commission on May 3, 2004, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling (714) 247-8348.
#
# #